KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Operating Income (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Operating Income for 17 consecutive years, with $268.6 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Income rose 1386.07% year-over-year to $268.6 million; the TTM value through Mar 2026 reached $752.1 million, up 751.92%, while the annual FY2025 figure was $501.6 million, 383.56% up from the prior year.
  • Operating Income hit $268.6 million in Q1 2026 for Alnylam Pharmaceuticals, up from $131.7 million in the prior quarter.
  • Across five years, Operating Income topped out at $368.0 million in Q3 2025 and bottomed at -$258.0 million in Q3 2022.
  • Average Operating Income over 5 years is -$27.9 million, with a median of -$76.9 million recorded in 2024.
  • Year-over-year, Operating Income tumbled 135.96% in 2024 and then skyrocketed 1386.07% in 2026.
  • Alnylam Pharmaceuticals' Operating Income stood at -$188.6 million in 2022, then soared by 38.28% to -$116.4 million in 2023, then increased by 9.66% to -$105.2 million in 2024, then surged by 225.26% to $131.7 million in 2025, then skyrocketed by 103.95% to $268.6 million in 2026.
  • According to Business Quant data, Operating Income over the past three periods came in at $268.6 million, $131.7 million, and $368.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.